Loading...
Loading...
Immunomedics, Inc.
IMMU, a
biopharmaceutical company primarily focused on the development of monoclonal
antibody-based products for the targeted treatment of cancer, autoimmune and
other serious diseases, today reported that its lead antibody drug candidate,
epratuzumab, has a distinct way of reducing the immune response of B cells,
which, in an autoimmune disease such as lupus, are responsible for producing
antibodies that attack the patient's own body.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in